The crucial role of SRPK1 in IGF-1-induced EMT of human gastric cancer

Wang, Hong; Wang, Chunlei; Tian, Wenling; Yao, Yanfen

doi:10.18632/oncotarget.20048

Cited by 21 publications

(27 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Thus, IGF-1 is a well-documented cytokine in cell growth and survival, oncogenic transformation, and cancer progression. [2][3][4] Apart from the diverse effects of IGF-1 on various tissues, IGF-1 can also be released by stromal cells in the bone marrow (BM), and distant organs including the liver and other tissues, and functions as a systemic regulator on hematopoiesis. 5 IGF-1 has been reported to be not only a crucial mediator of endosteal niche reorganization, consequently facilitating hematopoietic stem cell (HSC) engraftment, but also plays important roles in erythrocytosis and lymphocytopoiesis.…”

Section: Introductionmentioning

confidence: 99%

“…16,17 PI3K-AKT has been reported to enhance protein synthesis and cellular metabolism via mammalian target of rapamycin (mTOR) and to increase survival via p53, NF-kB, BAD/Bcl2, and FOXOs, whereas MEK-ERK1/2 activation mainly leads to increased cellular expansion. 3,18 Platelets are produced by megakaryocytes (MKs), which originate from HSCs and then undergo several consecutive molecular and biological stages that are unique to this cell lineage, including MK differentiation, expansion, maturation, proplatelet formation (PPF) and platelet release. 19 Therefore, the output of platelet production will be compromised if any stage is influenced, and various hematopoietic cytokines have been reported to regulate different steps of thrombopoiesis through activation of MEK-ERK1/2, PI3K-Akt or JAK-STAT signaling pathways.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

IGF-1 facilitates thrombopoiesis primarily through Akt activation

Chen

Shen

et al. 2018

Blood

View full text Add to dashboard Cite

It is known that insulin-like growth factor-1 (IGF-1) also functions as a hematopoietic factor, although its direct effect on thrombopoiesis remains unclear. In this study, we show that IGF-1 is able to promote CD34 cell differentiation toward megakaryocytes (MKs), as well as the facilitation of proplatelet formation (PPF) and platelet production from cultured MKs. The in vivo study demonstrates that IGF-1 administration accelerates platelet recovery in mice after 6.0 Gy of irradiation and in mice that received bone marrow transplantation following 10.0 Gy of lethal irradiation. Subsequent investigations reveal that extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt activation mediate the effect of IGF-1 on thrombopoiesis. Notably, Akt activation induced by IGF-1 is more apparent than that of ERK1/2, compared with that of thrombopoietin (TPO) treatment. Moreover, the effect of IGF-1 on thrombopoiesis is independent of TPO signaling because IGF-1 treatment can also lead to a significant increase of platelet counts in homozygous TPO receptor mutant mice. Further analysis indicates that the activation of Akt triggered by IGF-1 requires the assistance of steroid receptor coactivator-3 (SRC-3). Therefore, our data reveal a distinct role of IGF-1 in regulating thrombopoiesis, providing new insights into TPO-independent regulation of platelet generation.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

IGF-1 facilitates thrombopoiesis primarily through Akt activation

Chen

Shen

et al. 2018

Blood

View full text Add to dashboard Cite

show abstract

“…Similarly, in colorectal cancer, SRPK1 was overexpressed in both cancer and its precursor, adenoma, compared to the normal colonic tissue [22,31,36,[38][39][40]; its high expression was also linked with higher grade and stage colorectal cancers, presence of lymph node metastases, in addition to shorter overall and recurrence-free survival [31,36,38,39]. In stomach cancer, high SRPK1 was also found compared to the normal stomach histology [31,[41][42][43][44] and was associated with higher grade, stage, larger tumor size, lymph node metastases, and shorter overall survival [41,43,44]. Liver cancer was also characterized by SRPK1 overexpression, while the latter was correlated with higher stage, larger tumor size, and shorter survival [45][46][47].…”

Section: Cancer Type (Primary Location)mentioning

confidence: 95%

“…The IGF-1/SRPK1 pathway regulates EMT [44] Liver ↑SRPK1 promoted migration, invasion, and EMT in vitro; SRPK1 expression was inversely correlated with miR-1296 in vivo and in vitro…”

Section: Srpk1-mediated Mechanism(s)/ Pathway(s) Involved Referencementioning

confidence: 99%

“…Concerning other epithelial cancer types, SRPK1 downregulation suppressed migration and invasion in skin basal cell carcinoma [64]. It also suppressed proliferation, migration, and invasion in stomach cancer preclinical models through various mechanisms, including interactions with the AKT, ERK (extracellular signal regulated kinase) and small nucleolar RNA-mediated pathways, also the microRNA miR-126 [41][42][43][44]. In liver cancer, it suppressed proliferation, migration, and invasion [45,47].…”

Section: Srpk1-mediated Mechanism(s)/ Pathway(s) Involved Referencementioning

confidence: 99%

See 1 more Smart Citation

Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives

Nikas

Themistocleous

Paschou

et al. 2019

Cells

View full text Add to dashboard Cite

Cancer, a heterogeneous disease composed of tumor cells and microenvironment, is driven by deregulated processes such as increased proliferation, invasion, metastasis, angiogenesis, and evasion of apoptosis. Alternative splicing, a mechanism led by splicing factors, is implicated in carcinogenesis by affecting any of the processes above. Accumulating evidence suggests that serine-arginine protein kinase 1 (SRPK1), an enzyme that phosphorylates splicing factors rich in serine/arginine domains, has a prognostic and potential predictive role in various cancers. Its upregulation is correlated with higher tumor staging, grading, and shorter survival. SRPK1 is also highly expressed in the premalignant changes of some cancers, showing a potential role in the early steps of carcinogenesis. Of interest, its downregulation in preclinical models has mostly been tumor-suppressive and affected diverse processes heterogeneously, depending on the oncogenic context. In addition, targeting SRPK1 has enhanced sensitivity to platinum-based chemotherapy in some cancers. Lastly, its aberrant function has been noted not only in cancer cells but also in the endothelial cells of the microenvironment. Although the aforementioned evidence seems promising, more studies are needed to reinforce the use of SRPK1 inhibitors in clinical trials. major area of research in the field of intratumor heterogeneity, while their presence is associated with cancer recurrence, metastasis, and resistance to chemotherapy [7].Cancer prognosis depends on multiple factors that affect survival. Tumor staging, traditionally performed with the TNM system, is the most important prognostic factor. It refers to the size of the tumor (T), also the extent of its spread to the regional lymph nodes (N) or distant metastatic sites (M) [8,9]. Grading refers to the histologic picture of the tumor, more specifically, how closely it looks compared to the normal tissue it derives from (differentiation) [10,11]. Both the presence of distant metastases (e.g., in lungs, brain, liver, bones) and poor differentiation are associated with a dismal prognosis [9,11]. The molecular subtype of specific cancers is also critical for cancer survival. For instance, breast cancer has diverse intrinsic subtypes-luminal A and B, human epidermal growth factor receptor 2-enriched (HER2-enriched), and basal-like-that directly impact prognosis [12][13][14]. Luminal breast cancers are most commonly hormone-positive, overexpressing estrogen receptors (ER), and are associated with a better prognosis than HER2-enriched or basal-like breast cancers (BLBCs) [12][13][14][15]. BLBCs, which most commonly present with a triple-negative phenotype, have been linked with the worst prognosis and highest metastatic potential of all breast cancer molecular subtypes [13,16,17].Alternative splicing is the process that removes introns and adds exons in various combinations resulting in multiple mRNA products hence protein transcripts. As a result, it maintains the protein diversity and cellular homeostasis [18]. The...

show abstract

SRPKs: a promising therapeutic target in cancer

Tufail

2023

Clin Exp Med

View full text Add to dashboard Cite

The crucial role of SRPK1 in IGF-1-induced EMT of human gastric cancer

Cited by 21 publications

References 21 publications

IGF-1 facilitates thrombopoiesis primarily through Akt activation

IGF-1 facilitates thrombopoiesis primarily through Akt activation

Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives

SRPKs: a promising therapeutic target in cancer

Contact Info

Product

Resources

About